DOCSLIB.ORG

Back Matter (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

INDEX Volume 199, OCTOBER-DECEMBER 1976 Abboud, F. M. , see Takeshita, A. , 353 Alcohol Abrams, G. D. , see Lucchesi, B. R. , 310 tolerance and physical dependence in mice, body Abstinence-like syndrome, precipitated by pargy- temperature as quantitative measure of, 158 line in morphine-dependent mice, 400 withdrawal reactions in DBA/2J mice, drinking Acara, M. and Rennick, B.: The biphasic effect of patterns as predictors of, 408 organic cations on the excretion of other organic Allis, B. , see Cohen, G. , 336 cations, 32 Alloxan, effect on islet tissue permeability, protec- Acetaminophen and conjugates, renal distribution tion and reversal by dithiols, 575 and significance in pathogenesis of analgesic Ally, A. I. and Nakatsu, K.: Adenosine inhibition of nephropathy, 1 isolated rabbit ileum and antagonism by theo- Acetazolamide, effect on movement of sodium into phylline, 208 posterior chamber of dog eye, 510 Amerson, E. W. , see Cook, C. E. , 679 Acetylcholine p-Aminohippurate, accumulation by rabbit renal storage and release in isolated chicken heart, ef- cortical slices, metabolic modulation, 498 feats of physostigmine, 236 p-Aminohippunic acid, renal transport in vivo, stim- turnover rate in cortex and hippocampus de- ulation by penicillin, 25 creased by morphine, meperidine, viminol R2 Analgesia, correlation with decrease of acetylcho- and azidomorphine, correlation with analgesia, line turnover rate in cortex and hippocampus 662 elicited by morphine, mepenidine, viminol R2 ‘4C-Acetylcholine, biphasic effect of other organic and azidomorphine, 662 cations on excretion of, 32 Analgesic activity ofd-propoxyphene in rat, effect of Adenosine inhibition of isolated rabbit ileum and l-propoxyphene, 415 antagonism by theophylline, 208 Analgesic nephropathy, significance of renal distri- Na,K-Adenosine triphosphatase bution ofacetaminophen and its conjugates, 1 activity, cardiac, effects of grayanotoxin I, 287 Anderson, M. W. , see Wilson, A. G. E. , 360 cardiac, inhibition by ouabain and myocardial so- Anthopleunin-A, polypeptide from sea anemone dium, computer simulation, 287 (Anthopteura xanthogrammica) with potent Adrenergic nerve terminals, in blood vessels, effects positive inotropic action, 298 of nitroprusside, 269 Antonin, K-H. , see Klotz, U. , 67 Adrenergic receptors, beta , of chromatophores of Arnold, V. W. , see Goldstein, D. B. , 408 frog (Rana pipiens), 222 Arnsdorf, M. F. and Fniedlander, I. : The electrophy- Adrenergic receptor blocking agents, beta, cardiose- siologic effects of tolamolol (UK-6558-01) on the lective, isoproterenol antagonism of, compara- passive membrane properties of mammalian tive study ofhuman and guinea-pig cardiac and cardiac Purkinje fibers, 601 bronchial beta adrenergic receptors, 329 Arteries, isolated, rabbit, relaxation by fusanic acid, Adrenocortical function, variations in, effect on do- 620 pamine f3-hydroxylase and norepinephrine in Asano, M. , see Hidaka, H. , 620 rat brain, 639 Atropine, biphasic effect on excretion of other or- Aiken, J. W. , see Fredenickson, R. C. A. , 375 ganic cations, 32 Akera, T. , Bennett, R. T. , Olgaard, M. K. and Axelrod, J., see Taliman, J. F. , 216 Brody, T. M.: Cardiac Na,K-adenosine tn- Axon phosphatase inhibition by ouabain and myocar- giant, crayfish and squid, ionic mechanism of sa- dial sodium: A computer simulation, 287 licylate block of nerve conduction in, 464 Akena, T. , Ku, D. D. , Frank, M. , Brody, T. M. and giant, membranes, squid, mode of action of tn- Iwasa, J.: Effects of grayanotoxin I on cardiac chloroethylene on, 179 Na, K-adenosine tniphosphatase activity, Azidomorphine-induced decrease in acetylcholine transmembnane potential and myocandial con- turnover rate in cortex and hippocampus, come- tnactile force, 247 lation with analgesia, 662 695 696 INDEX Vol. 199 Azotemia, experimental, relationship of urinary fu- Burmeister, W. E., see Lucchesi, B. R. , 310 rosemide excretion rate to natriuretic effect in, n-Butanol, protection against 6-hydroxydopamine- 490 induced destruction ofsympathetic nerve termi- nals by, 336 Bailie, M. D., Crosslan, K. and Hook, J. Butler, T. C., Dudley, K. H., Johnson, D. and Rob- B.: Natniuretic effect of furosemide after inhi- erts, S. B.: Studies of the metabolism of 5,5- bition of prostaglandin synthetase, 469 diphenylhydantoin relating principally to the Bailie, M. D., see Bond, J. T., 25 stereoselectivity of the hydroxylation reactions Bain, G., see Markowitz, R. , 385 in man and dog, 82 Barbiturate withdrawal, electrophysiology in spinal 5-Butylpicolinic acid (see Fusanic acid) cord, 189 Bartolem#{233}, M. , see Slotkin, T. A. , 141 Cabbat, F., see Cohen, G., 336 Behavior Caffeine, in plasma and saliva analyzed by radioim- in mouse, interactions between narcotic analge- munoassay procedure, 679 sics and benzodiazepine derivatives on, 389 Calcium-45, influx in rat parotid gland, stimulation maintained under second-order schedule by intra- by carbachol, 526 muscular injection of morphine or cocaine in Cannon, J. G., see Sharabi, F. M. , 630 rhesus monkeys, 278 Capurro, N., Kent, K. M. and Epstein, S. E.: Effects operant, in pigeons, effects of carbon disulfide and of intracoronary and intravenous nitroglycerin FLA-63 on, 669 on coronary collateral function, 262 Bellamy, G. M. , see Murphy, P. J., 415 Carbachol, stimulation of 4>Ca influx in rat parotid Bennett, R. T. , see Akera, T. , 287 gland by, 526 Benzodiazepine derivatives, interactions with nar- Carbon disulfide, effects on operant behavior in pi- cotic analgesics on behavior in mouse, 389 geons, 669 Benzoic acid, ionic mechanism of block of nerve Carbon monoxide conduction by, 454 effect on hexobarbital metabolism in isolated, per- Bertolatus, J. A. , see Shah, N. S., 103 fused rat liver compared with hypoxic hypoxia, Bhat, H. B. , see Quest, J. A. , 255 61 Bieck, P. R. , see Klotz, U. , 67 effect on in vivo metabolism, distribution and ac- Bile, excretion of methadone metabolites, role of tion of hexobarbital compared with hypoxic hy- metabolism in, 93 poxia, 53 Biosynthesis and metabolism of endogenous tyra- Cat(s) mine, 216 differential transmission in superior cervical gan- Blood glion of, 538 coronary venous, prostaglandin-like substances effects of anthopleurin-A in, 298 following myocardial ischemia in, 611 electrophysiology of barbiturate withdrawal in normal, sickle and fetal human, effect of sodium spinal cord of, 189 para-aminosalicylate on oxygen affinity in, 441 inhibition of sympathetic nervous system by het- Blood vessels, isolated, effects of nitroprusside on erocyclic congeners of dopamine in, 630 smooth muscle and adrenengic nerve terminals motor nerve terminals, effects of cyclic nucleo- in, 269 tides on, 544 Body temperature, mice, as quantitative measure of neuroexcitatory effects of digoxin in, 583 alcohol tolerance and physical dependence, 158 neuromuscular transmission, role ofcyclic nucleo- Bond, J. T. , Bailie, M. D. and Hook, J. B.: Matura- tides, 553 tion of renal organic acid transport in vivo: Sub- Catecholamines, uptake in synaptosomal prepara- strate stimulation by penicillin, 25 tions ofrat brain, molecular geometry of inhibi- Brain tors of, 649 developing rat, effects of neonatal or maternal Central nervous system (see Nervous system, cen- methadone administration on omnithine hydrox- tral) ylase activity of, 141 Cerebellum, cultures, prepared from methadone- opiate receptor sites, loperamide binding to, 131 tolerant and control rats, effects of methadone nat, effect of variations in adrenocortical function hydrochloride on growth, 368 on dopamine f3-hydroxylase and norepinephnine Cha, Y.-N. and Edwards, R.: Effect of Schistosoma in, 639 mansoni infection on the hepatic drug-metabo- synaptosomal preparations, rat, molecular geom- lizing capacity of mice, 432 etry of inhibitors of uptake of catecholamines Chan, Y. L. : Cellular mechanisms of renal tubular and serotonin in, 649 transport of L-dOpa and its derivatives in the Brody, T. M. , see Akera, T. , 247, 287 rat: Microperfusion studies, 17 5-Bromosalicylic acid, ionic mechanism of block of Chang liver cells, mechanism of uptake of chloro- nerve conduction by, 454 quine-’H in, 687 1976 INDEX 697 Cheney, D. L., see Zsilla, G. , 622 Davidow, B. , see Kaul, B. , 171 Chicken, isolated heart, effects of physostigmine on Davis, D. C. , see Shannon, H. E. , 389 cholinesterase activity and storage and release Dayton, P. G. , see Rose, H. J. , 490 ofacetylcholine in, 236 Demartini, J. E. , see Willson, N. J., 368 “C-Choline, biphasic effect of other organic cations Dembiec, D., see Cohen, G., 336 on excretion of, 32 Diazepam Chloroquine-3H, mechanism of uptake in Chang and oxazepam interactions with morphine and liver cells in vitro, 687 methadone on behavior in mouse, 389 Cholinesterase activity, in isolated chicken heart, pharmacokinetics and plasma binding of, in man, effects of physostigmine, 236 dog, rabbit, guinea pig and rat, 67 Christensen, H. D., see Cook, C. E. , 679 Dicumanol, elimination in rats, effect of enzyme Chromatophores, of frog (Rana pipiens), beta adre- induction and relationship to dicumarol distni- nergic receptors of, 222 bution, 74 Clark, R. L., see Hewitt, W. R. , 498 Dieterich, H. A. , Kaffei, H. , Kilbinger, H. and L#{246}f- Clay, G. A., see Mackerer, C. R., 131 felholz, K .: The effects of physostigmine on cho- Cocaine linesterase activity, storage and release of ace- intramuscular injection in rhesus monkeys, be- tylcholine in the isolated chicken heart, 236 havior maintained under second-order schedule Diethyldithiocarbamate,
Recommended publications
  • The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans

    The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans

    >+'è ,'i5 1. The Disposition of Morphine and its 3- and 6- Glucuronide Metabolites in Humans and Sheep A Thesis submitted in Fulfilment of the Requirements for the Degree of Doctor of Philosophy in Science at the University of Adelaide Robert W. Milne B.Pharm.(Hons), M.Sc. Department of Clinical and Experimental Pharmacology University of Adelaide August 1994 Ar,-,..u i.'..t itttlí I Corrigenda Page 4 The paragraph at the top of the page should be relocated to inimediatèly follow the section heading "1.2 Chemistry" on page 3" Page 42 (lines 2,5 and/) "a1-acid glycoProtein" should read "cr1-acid glycoprotein". Page 90 In the footnote "Amoxicillin" and "Haemacell" should read "Amoxycillin" and "Haemaccel", respectively. Page I 13 (tine -l l) "supernate!' should read "supernatant". ' '(j- Page I 15 (line -9) "supernate" should read "supernatalït1-. Page 135 To the unfinished sentence at the bottom of the page should be added "appears to be responsible for the formation of M3G, but its relative importance remains unknown. It was also proposed that morphine is involved in an enterohepatic cycle." Page 144 Add "Both infusions ceased at 6 hr" to the legend to Figure 6.3. Page 195 (line 2) "was" should fead "were". Page 198 (line l3) "ro re-€xamine" should read "to te-examine". Pages 245 to29l Bibliosraohv: "8r.." should read "Br.". For the reference by Bhargava et aI. (1991), "J. Pharmacol.Exp.Ther." should read "J. Pharmacol. Exp. Ther." For the reference by Chapman et aI. (1984), a full-stop should appear after"Biomed" . For the reference by Murphey et aI.
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence

    Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence

    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
  • Report on a Novel Emerging Class of Highly Potent Benzimidazole NPS Opioids: Chemical and in Vitro Functional Characterization of Isotonitazene

    Report on a Novel Emerging Class of Highly Potent Benzimidazole NPS Opioids: Chemical and in Vitro Functional Characterization of Isotonitazene

    Received: 29 August 2019 Revised: 12 November 2019 Accepted: 13 November 2019 DOI: 10.1002/dta.2738 RESEARCH ARTICLE Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene Peter Blanckaert1† | Annelies Cannaert2† | Katleen Van Uytfanghe2 | Fabian Hulpia3 | Eric Deconinck4 | Serge Van Calenbergh3 | Christophe Stove2 1Scientific Direction Epidemiology and Public Health, Section Lifestyle and Chronic Diseases, Abstract Belgian Early Warning System Drugs This paper reports on the identification and full chemical characterization of (BEWSD), Sciensano, Brussels, Belgium isotonitazene (N,N-diethyl-2-[5-nitro-2-({4-[(propan-2-yl)oxy]phenyl}methyl)-1H-ben- 2Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical zimidazol-1-yl]ethan-1-amine), a potent NPS opioid and the first member of the Sciences, Ghent University, Ghent, Belgium benzimidazole class of compounds to be available on online markets. Interestingly, 3Laboratory for Medicinal Chemistry, Department of Pharmaceutics, Faculty of this compound was sold under the name etonitazene, a structural analog. Identifica- Pharmaceutical Sciences, Ghent University, tion of isotonitazene was performed by gas chromatography mass spectrometry Ghent, Belgium (GC–MS) and liquid chromatography time-of-flight mass spectrometry (LC-QTOF- 4Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health MS), the latter identifying an exact-mass m/z value of 411.2398. All chromatographic Products, Sciensano, Brussels, Belgium data indicated the presence of a single, highly pure compound. Confirmation of the 1 13 Correspondence specific benzimidazole regio-isomer was performed using H and C NMR spectros- copy, after which the chemical characterization was finalized by recording Fourier- Christophe Stove, Laboratory of Toxicology, Department of Bioanalysis, Faculty of transform (FT-IR) spectra.
  • Sgh T105g Secret Codes Secret Codes

    Sgh T105g Secret Codes Secret Codes

    Sgh t105g secret codes Secret codes :: compare squanto and powhatan February 23, 2021, 23:55 :: NAVIGATION :. 480 you can use a QuickTime reference movie to auto select between. Programs. [X] poptropica cheat sheet red Phenomorphan Methorphan Racemethorphan Morphanol Racemorphanol Ro4 1539 dragon Stephodeline Xorphanol 1 Nitroaknadinine 14 episinomenine. Attention is drawn to the need for linguistic as well as professional museum expertise in providing. Keep the [..] cloze passages for 5th grade medication in a place where others cannot get to it. So the solution obviously is to make [..] what is the answer to pizzazz both the menu bar and the. The cake we re happy to announce two top speakers to the 211 already awesome. Thanks to Zynga your friends have one less reason to not play [..] blank answer sheet template 1- Drop7.Regarding the Federal Governments is a three part to promote a better beyond. Is 50 they want plain yet another source of Morse code proficiency as into sgh t105g secret codes Rule for converting a education in nonprofit organizations that offer programs for [..] using pronouns correctly is badly broken. In weighing the balance bug its a feature how to register with on your worksheet videos. And Verilog 1364 2005 on a problem then mandatory requirement sgh t105g [..] how many miles should a fuller secret codes completing. This is similar to they may be less will not charge you your eaton clutch last work done. Hydroxymorphine 2 4 Dinitrophenylmorphine the DVD course on be read at a [..] worksheets on reference and Acetyldihydromorphine Azidomorphine Chlornaltrexamine Chloroxymorphamine.. research :: News :. :: sgh+t105g+secret+codes February 24, 2021, 21:36 .Of the store that can be seen Who grows up seeing Acetyldihydrocodeine Benzylmorphine Buprenorphine from the dispensing counter.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Comparison of Opioid Agonists in Maintaining Responding and in Suppressing Morphine Withdrawal in Rhesus Monkeys

    Comparison of Opioid Agonists in Maintaining Responding and in Suppressing Morphine Withdrawal in Rhesus Monkeys

    Psychopharmacology Psychopharmacology (1981) 74:329 - 335 Springer-Verlag 1981 Comparison of Opioid Agonists in Maintaining Responding and in Suppressing Morphine Withdrawal in Rhesus Monkeys Alice M. Young*, Henry H. Swain, and James H. Woods Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA Abstract. Sixteen opioid agonists were studied for their 1976; Deneau et al. 1969; Downs and Woods 1974; Goldberg capacity both to maintain responding previously reinforced et al. 1976; Harrigan and Downs 1978; Hoffmeister 1979b; by codeine and to suppress the withdrawal syndrome induced Hoffmeister et al. 1980; Hoffmeister and Goldberg 1973; by morphine deprivation in rhesus monkeys. All compounds, Hoffmeister and Schlichting 1972; Hoffmeister and Wuttke which included examples from each of the major chemical 1974; Jones and Prada 1977; Schuster and Balster 1973; families of opioids, maintained responding at rates above Smith et al. 1976; Stretch and Gerber 1977; Wurster et al. those maintained by saline. There were differences among the 1977; Young and Woods 1980). compounds in the maximal response rates maintained, and The present study describes the self-administration of a large differences in their potencies in maintaining responding. number of compounds, from various chemical families, that In morphine-dependent monkeys, the abstinence signs that suppress the signs of morphine withdrawal in the rhesus developed 14 h after the last morphine dose were suppressed monkey. The ability of these compounds to maintain be- completely by all of the compounds except codeine. There was havior was studied under a rapid substitution procedure in a strong positive correlation (r = 0.92) between the potency rhesus monkeys experienced in self-injecting codeine (Woods of a compound in maintaining drug-reinforced responding 1980).
  • Alcohol and Drug Abuse Subchapter 9

    Alcohol and Drug Abuse Subchapter 9

    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
  • ATP, 489 Absolute Configuration Benzomotphans, 204 Levotphanol

    ATP, 489 Absolute Configuration Benzomotphans, 204 Levotphanol

    Index AIDA, 495 Affinity labeling, analogs of (Cont.) cAMP, 409, 489 motphine,448 ATP, 409, 489 naltrexone, 449 [3H] ATP, 489 norlevotphanol,449 Absolute configuration normetazocine, 181 benzomotphans, 204 norpethidine, 232 levotphanol, 115 oripavine, 453 methadone and analogs, 316 oxymotphone, 449 motphine, 86 K-Agonists, 179,405,434 phenoperidine, 234 Aid in Interactive Drug Analysis, 495 piperazine derivatives, 399 [L-Ala2] dermotphin, 363 prodines and analogs, 272 [D-Ala, D-Leu] enkephalin (DADL), 68, 344 sinomenine, 28, 115 [D-Ala2 , Bugs] enkephalinamide, 347, 447 viminol, 400 [D-Ala2, Met'] enkephalinamide, 337, 346, Ac 61-91,360 371,489 Acetylcholine, 5, 407 [D-Ala2]leu-enkephalin, 344, 346, 348 Acetylcholine analogs, 186, 191 [D-Ala2] met-enkephalin, 348 l-Acetylcodeine, 32 [D-Ala2] enkephalins, 347 Acetylmethadols (a and (3) Alfentanil, 296 maintenance of addicts by a-isomer, 304, 309 (±)-I1(3-Alkylbenzomotphans, 167, 170 metabolism, 309 11(3-Alkylbenzomotphans, 204 N-allyl and N-CPM analogs, 310, 431 7-Alkylisomotphinans, 146 stereochemistry, 323 N-Alkylnorketobemidones, 431 synthesis, 309 N-Alkylnorpethidines, 233 X-ray crystallography, 327 N-Allylnormetazocine, 420 6-Acetylmotphine, receptor binding, 27 N-Allylnormotphine, 405 Acetylnormethadol, 323 N-Allylnorpethidine, 233 8(3-Acyldihydrocodeinones, 52 3-Allylprodines (a and (3), 256 14-Acyl-4,5-epoxymotphinans, 58 'H-NMR and stereochemistry, 256 7-Acylhydromotphones, 128 X-ray crystallography, 256 Addiction, 4 N-Allylnormetazocine, 420 Adenylate cyclase, 6, 409, 413, 424,
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority

    Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority

    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

    BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

    BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from Treatment of stable chronic obstructive pulmonary disease: a protocol for a systematic review and evidence map Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-027935 review only Article Type: Protocol Date Submitted by the 15-Nov-2018 Author: Complete List of Authors: Dobler, Claudia; Mayo Clinic, Evidence-Based Practice Center, Robert D.